Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy

Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy. A Prospective Placebo Double Blind Study

Background: Identification of new biomarkers with potential predictive and prognostic role has contributed unequivocally to breast cancer treatment.

Although traditionally endocrine therapy is based on hormonal receptors status (estrogen - ER and progesterone- PR), some patients become hormone resistant. In order to identify a possible profile associated to hormonal resistance, some biomarkers have been assessed after short period primary hormone therapy (HT).

Objectives: To compare the expression of Ki-67, Bcl2, Bax, Bak, ER and e PR in postmenopausal women with ER positive invasive ductal carcinomas (IDC), prior and after tamoxifen and anastrozole in short term hormone therapy.

Inclusion Criteria:

• Invasive breast cancer post-menopausal women
• Estrogen and/or progesterone receptor positive

Exclusion Criteria:

• Patients with endocrine disease
• Hormone therapy users or those who had been pregnant in the last 12 months before the diagnosis
• Patients with a negative expression for estrogen and/or progesterone receptors
• Women with a history of thromboembolism
• Patients who had previously undergone any treatment for breast cancer